Peptide Alarm Therapy (PAT)

Phase 1Small molecule

MMasonic Cancer Center, University of Minnesota

Peptide Alarm Therapy (PAT) is one of 4 small molecule programs targeting Solid Tumor Cancers. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Solid Tumor CancersRecruiting

Solid Tumor CancersPhase 1

Recruiting

Competition

Competitive Landscape

4 competitors in Solid Tumor Cancers

#DrugCompanyPhaseTrials

Vectibix

Amgen

Phase 2

1 2

Lumakras

Amgen

Phase 2

1 3

Ayvakit Sprinkle

MMemorial Sloan Kettering Cancer Center

Phase 1

1 4

Peptide Alarm Therapy (PAT)

MMasonic Cancer Center, University of Minnesota

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Solid Tumor Cancers

NCT05338658

Clinical

Trials by Indication[1]

Solid Tumor Cancers1 trial

Study of PAT in Patients With Solid Tumor Cancers

Recruiting·MMasonic Cancer Center, University of Minnesota·Phase 1·NCT05338658·21 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Peptide Alarm Therapy (PAT). U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Peptide Alarm Therapy (PAT) compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Peptide Alarm Therapy (PAT). EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Masonic Cancer Center, University of Minnesota company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: MMasonic Cancer Center, University of Minnesota

Peptide Alarm Therapy (PAT)

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Solid Tumor Cancers1 trial

References

Drug Info

Quick Facts

Related News